Male breast cancer in the state of Florida (1981-2009)
Methods: Data from the Florida Cancer Data System (FCDS), the Agency for Health Care Administration, and the Census were linked for male breast cancer patients (n=2,962). We calculated descriptive statistics on sociodemographic, clinical, tumor and treatment characteristics, and for median survival time (MST).
Results: Sociodemographic characteristics included: 91.4% White, 7.8% Black, 8.0% Hispanic; 69.2% married, 11% never married; 51.8% never smoked, 31.5% formerly smoked, 16.6% currently smoke (for those with known smoking status). Clinical and tumor characteristics: 25.5% with no other comorbidities, 52.0% with >4 comorbidities; 45.6% localized, 31.1% regional, and 6.1% distant stage; 69.6% ductal carcinoma. Treatments: 20.4% chemotherapy; 89.6% radiation therapy; 89.3% surgery, of which 48.1% were total or radical mastectomy. Overall MST in years was 7.9, but shorter in Blacks (5.5) than Whites (8.1), and in non-Hispanics (7.9) than Hispanics (8.4). MST increased sharply from patients living in areas of lowest socioeconomic status to highest (5.7, 7.4, 8.2, 9.0).
Conclusion: Less is known about male breast cancer, and there are differences from breast cancer in women. For example, women's MST is 11.8 years which is 4-years longer than men. Understanding the disease and patient characteristics will help us improve screening, treatments, and outcomes.
Learning Areas:Chronic disease management and prevention
Diversity and culture
List the sociodemographic characteristics of male breast cancer patients in our sample. Compare the median survival times among race, ethnicity, and socioeconomic status. Discuss the clinical and tumor characteristics of men with breast cancer.
Qualified on the content I am responsible for because: I am qualified to be an abstract author on the content because I have been volunteering with this Florida Biomedical research group for the past year and I am a second year medical student studying cancer disparities in male and female patients
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.